Regenxbio (RGNX) Revenue (2014 - 2025)

Regenxbio's Revenue history runs 12 years deep, the most recent figure standing at $27.1 million for Q4 2025.

• On a quarterly basis, Revenue rose 27.97% year-over-year to $27.1 million in Q4 2025; TTM through Dec 2025 was $165.3 million, a 100.11% increase from a year earlier, with the FY2025 full-year figure at $156.3 million, up 87.53% from the prior year.
• Revenue fell to $27.1 million in Q4 2025 per RGNX's latest filing, from $29.7 million in the prior quarter.
• Across five years, Revenue topped out at $398.7 million in Q4 2021 and bottomed at $15.3 million in Q1 2024.
• The 5-year median for Revenue is $23.2 million (2022), against an average of $46.1 million.
• Across the five-year window, Revenue soared 1758.96% in 2021 and slumped 92.14% in 2022, its largest moves.
• Year by year, Revenue stood at $398.7 million in 2021, then slumped by 92.14% to $31.3 million in 2022, then dropped by 29.13% to $22.2 million in 2023, then decreased by 4.5% to $21.2 million in 2024, then grew by 27.97% to $27.1 million in 2025.
• Per Business Quant, the three latest RGNX Revenue figures stand at $27.1 million (Q4 2025), $29.7 million (Q3 2025), and $21.4 million (Q2 2025).